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GUEST EDITORIAL
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It has been known for many years that porphyrin-based compounds interact with light and, in
particular, that some haematoporphyrin-derived substances concentrate in tumour tissue and can be
activated by light to produce a characteristic fluorescence.
The chance discovery of a material known as 'haematoporphyrin derivative' (HPD) led to the
potential for useful treatment, because of its tumour localisation properties and because activation by
light produces a phototoxic reaction which destroys tumour cells. This potential has been realised more
recently because of developments in laser and optical fibre technology which have allowed the drug and
the light to be brought together in such a way as to be clinically useful. This is the basis of the
treatment known as photodynamic therapy (PDT). Much experimental and clinical work has been
carried out over the past 10 years and it is opportune to review achievements and prospects at this time.
Clinical treatment is, in principle, very straightforward. About two or three days following
intravenous administration of photoactive drug, maximum selective concentration of drug in tumour
relative to surrounding healthy tissue is achieved. Laser light is then delivered to the tumour region and
cell destruction follows rapidly. The exact mechanism which determines drug concentration in tumour is
not entirely clear, but may be important in future manipulation of therapeutic ratio. Some animal
studies have shown levels of drug in tumour tissue which are eight to nine times higher than in
surrounding normal tissue, but it is more common to achieve a ratio of 2:1.
The mechanism of light and drug interaction in vitro suggests that there is a direct cell killing effect
which predominantly acts on cell membranes and is mediated by the production of singlet oxygen which
is cytotoxic (Hilf et al., 1984). While there seems to be a direct cytotoxic effect in vitro, there is a strong
suggestion that in vivo there is a major effect on tumour vasculature, which very rapidly collapses after
PDT so that the tumour cells may die of secondary anoxia. This has been supported in experiments
which have shown that if the tumour is explanted immediately after PDT, it continues to grow, whereas
if left in situ it succumbs to the effects of vascular collapse (Henderson et al., 1984). This may itself have
important implications for the targeting of treatment to tumour stromal blood vessels. Because of the
almost instantaneous shutdown of blood flow there is rapid cell kill which may affect both tumour and
normal tissue. Perhaps because of the mode of injury, however, which differs from other physical
treatments such as heat or radiation, the normal tissues appear to heal much better than equivalent
injury produced by other modalities and this may have an important bearing on the therapeutic ratio
that can be achieved (Gilson et al., 1988). The therapeutic ratio can also be improved by avoiding
transmission of light through the skin where there is considerable absorption in the first few millimetres
which contain melanin and where the major effect is likely to occur. This is not the case in mucous
membranes nor when light is delivered interstitially by introducing the optical fibre below the skin
surface.
To date the majority of research in PDT, and virtually all clinical treatment, has been performed
using HPD. This is an unsatisfactory mixture of compounds and much work has been directed at
isolating the fractions within this mixture that are the active components of PDT. It appears that an
aggregated fraction of haematoporphyrin within HPD is responsible for much of the tumour localising
properties and this is the basis of PhotofrinII, a second generation drug, which is a form of HPD
enriched in the localising fraction and which shows better tumour localisation.
The absorption spectrum of HPD shows a large peak at approximately 400 nm. Light of this
wavelength is so poorly penetrating, however, that it cannot be used to treat tumours more than 1 or
2mm thick. For this reason, 630nm (red) light is usually used to activate the drug and is chosen as
being the best compromise between drug activation and tissue penetration. Nevertheless, the penetration
of 630 nm light is still poor and is likely to have a range of 5-10mm. This gives extra emphasis to the
development of new drugs which can be activated by light of 700-800nm wavelengths. Considerable
work is therefore being put into the development of new photoactive drugs which have equally good as
or better localising properties than HPD, but can be activated by light of longer wavelengths which is
more penetrating in tissue, thereby facilitating treatment of larger tumour masses. The phthalocyanine
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group of compounds have already been shown to be better than HPD in animal systems, but have not
yet been used clinically (Spikes, 1986).
Monochromatic red light of the required intensity is best produced by a laser, which usually
incorporates a dye to give the required wavelength. The light can then be chanelled into optical fibres
which may be used either for surface lighting or transmission down an endoscope for insertion into
natural cavities or for direct implantation into tissue. This gives the treatment very wide applicability in
a range of tumour types and several thousand patients have been the subject of clinical study.
The clinical studies performed to date show, as may be expected from the physical characteristics of
light distribution, that the treatment is very effective for superficial malignancy, but not yet as effective
for more bulky tumours. Good results have been obtained in superficial bladder cancer, where the
interior of the bladder can be illuminated by an optical fibre inserted through a cystoscope and high
local control rates have been achieved with minimal morbidity (Benson, 1985). The same has been
shown in early lung cancer. Patients with X-ray negative early disease detected by cytology have shown
a high complete response to PDT and a number of 5-year survivors have now been reported following
this treatment (Kato et al., 1986). Similarly, patients with early cancer of the oesophagus, who have
been the subject of screening following treatment for other head and neck cancers, have shown a high
complete response rate to PDT because they have been detected at a stage when the tumours are still
superficial (Hayata et al., 1985). For more advanced disease, cure has rarely been attempted but very
effective palliation can be produced, usually by a single treatment which is painless (Thomas et al.,
1987).
The treatment has a number of side-effects, the most troublesome of which is prolonged skin photo-
sensitivity, which means it is necessary to advise patients to keep out of direct sunlight for 6-8 weeks
following treatment. Phototoxic reactions can be minimised by appropriate counselling, but it is
nevertheless a disadvantage, particularly in the southern hemisphere. Apart from this, however, the
treatment has generally been found to be associated with little morbidity and can often be done as an
outpatient procedure.
In conclusion, for superficial malignancy PDT has already shown that it can be curative. It has not,
however, been tested against other conventional treatments to confirm its superiority. For more
advanced malignancy, it already has a valuable palliative role, but advances in new drugs and in optical
fibre technology which will allow interstitial implantation of light give rise to hope that this treatment
may be applicable curatively to a wider range of malignancy with efficacy and safety.
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